Sector News

Arbor Pharmaceuticals explores $1 bln-plus sale – sources

October 3, 2014
Life sciences
(Reuters) – Arbor Pharmaceuticals LLC is exploring a sale that could fetch more than $1 billion for the privately-held specialty drugmaker, according to people familiar with the matter.
 
Atlanta, Georgia-based Arbor, which makes prescription drugs for cardiovascular, hospital and pediatric markets, is working with JPMorgan Chase on the potential sale, the people with knowledge of the situation said on Thursday, asking not to be named because the discussions are private.
 
Arbor joins a number of healthcare companies considering a sale at a time when robust buyout appetite from pharmaceutical and biotech companies is driving deal volumes to their highest levels in several years.
 
Representatives for Arbor could not be immediately reached for comment, while JPMorgan declined to comment.
 
The company has branded and generic prescription products for specialty focused conditions in various stages of development, and has 280 sales professionals, according to its website.
 
Its products include Nitrolingual Pumpspray, indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease; EDARBI for the treatment of high blood pressure in adults; and Zenzedi for the treatment of narcolepsy or attention deficit hyperactivity disorder in pediatric patients. (Reporting by Jessica Toonkel and Soyoung Kim in New York; Editing by Tom Brown)

Related News

March 6, 2021

Takeda takes full control of drug for rare epilepsies

Life sciences

The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones. 

March 6, 2021

Novartis signs Covid-19 vaccine manufacturing agreement with CureVac

Life sciences

Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.

March 6, 2021

Disney teams with Philips to bring its characters to pediatric imaging

Life sciences

A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.

Send this to a friend